tetano
Editor, Senior Moderator
J Endocr Soc
. 2020 Jul 21;4(9):bvaa102.
doi: 10.1210/jendso/bvaa102. eCollection 2020 Sep 1.
Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients
Francisco J Barrera[SUP] 1 2 3 [/SUP], Skand Shekhar[SUP] 4 5 [/SUP], Rachel Wurth[SUP] 4 [/SUP], Pablo J Moreno-Pena[SUP] 2 [/SUP], Oscar J Ponce[SUP] 3 6 [/SUP], Michelle Hajdenberg[SUP] 7 [/SUP], Neri A Alvarez-Villalobos[SUP] 1 2 3 8 [/SUP], Janet E Hall[SUP] 5 [/SUP], Ernesto L Schiffrin[SUP] 9 [/SUP], Graeme Eisenhofer[SUP] 10 [/SUP], Forbes Porter[SUP] 11 [/SUP], Juan P Brito[SUP] 3 [/SUP], Stefan R Bornstein[SUP] 12 13 14 [/SUP], Constantine A Stratakis[SUP] 4 [/SUP], Jos? Gerardo Gonz?lez-Gonz?lez[SUP] 1 2 8 [/SUP], Ren? Rod?guez-Guti?rrez[SUP] 1 2 3 8 [/SUP], Fady Hannah-Shmouni[SUP] 4 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (Covid-19) has affected millions of people and may disproportionately affect those with hypertension and diabetes. Because of inadequate methods in published systematic reviews, the prevalence of diabetes and hypertension and associated risks of poor outcomes in Covid-19 patients are unknown. We searched databases from December 1, 2019, to April 6, 2020, and selected observational peer-reviewed studies in English of patients with Covid-19. Independent reviewers extracted data on study participants, interventions, and outcomes and assessed risk of bias, and the certainty of evidence. We included 65 (15 794 participants) observational studies at moderate to high risk of bias. Overall prevalence of diabetes and hypertension was 12% (95% confidence interval [CI], 10-15; n = 12 870; I [SUP]2[/SUP]: 89%), and 17% (95% CI, 13-22; n = 12 709; I [SUP]2[/SUP]: 95%), respectively. In severe Covid-19, the prevalence of diabetes and hypertension were 18% (95% CI, 16-20; n = 1099; I [SUP]2[/SUP]: 0%) and 32% (95% CI, 16-54; n = 1078; I [SUP]2[/SUP]: 63%), respectively. Unadjusted relative risk for intensive care unit admission and mortality were 1.96 (95% CI, 1.19-3.22; n = 8890; I [SUP]2[/SUP]: 80%; P = .008) and 2.78 (95% CI, 1.39-5.58; n = 2058; I [SUP]2[/SUP]: 75%; P = .0004) for diabetics; and 2.95 (95% CI, 2.18-3.99; n = 1737; I [SUP]2[/SUP]: 0%; P < .001) and 2.39 (95% CI, 1.54-3.73; n = 3107; I [SUP]2[/SUP]: 66%; P < .001) for hypertensives. Neither diabetes (1.50; 95% CI, 0.90-2.50; n = 1991; I [SUP]2[/SUP]: 74%; P = .119) nor hypertension (1.48; 95% CI, 0.99-2.23; n = 2023; I [SUP]2[/SUP]: 69%; P = .058) was associated with severe Covid-19. In conclusion, the risk of intensive care unit admission and mortality for patients with diabetes or hypertension who developed Covid-19 is increased compared with those without these comorbidities.
Prospero registration number: CRD42020176582.
Keywords: Covid-19; SARS-CoV-2; diabetes mellitus; endocrinology; hypertension.
. 2020 Jul 21;4(9):bvaa102.
doi: 10.1210/jendso/bvaa102. eCollection 2020 Sep 1.
Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients
Francisco J Barrera[SUP] 1 2 3 [/SUP], Skand Shekhar[SUP] 4 5 [/SUP], Rachel Wurth[SUP] 4 [/SUP], Pablo J Moreno-Pena[SUP] 2 [/SUP], Oscar J Ponce[SUP] 3 6 [/SUP], Michelle Hajdenberg[SUP] 7 [/SUP], Neri A Alvarez-Villalobos[SUP] 1 2 3 8 [/SUP], Janet E Hall[SUP] 5 [/SUP], Ernesto L Schiffrin[SUP] 9 [/SUP], Graeme Eisenhofer[SUP] 10 [/SUP], Forbes Porter[SUP] 11 [/SUP], Juan P Brito[SUP] 3 [/SUP], Stefan R Bornstein[SUP] 12 13 14 [/SUP], Constantine A Stratakis[SUP] 4 [/SUP], Jos? Gerardo Gonz?lez-Gonz?lez[SUP] 1 2 8 [/SUP], Ren? Rod?guez-Guti?rrez[SUP] 1 2 3 8 [/SUP], Fady Hannah-Shmouni[SUP] 4 [/SUP]
Affiliations
- PMID: 32885126
- PMCID: PMC7454711
- DOI: 10.1210/jendso/bvaa102
Abstract
Coronavirus disease 2019 (Covid-19) has affected millions of people and may disproportionately affect those with hypertension and diabetes. Because of inadequate methods in published systematic reviews, the prevalence of diabetes and hypertension and associated risks of poor outcomes in Covid-19 patients are unknown. We searched databases from December 1, 2019, to April 6, 2020, and selected observational peer-reviewed studies in English of patients with Covid-19. Independent reviewers extracted data on study participants, interventions, and outcomes and assessed risk of bias, and the certainty of evidence. We included 65 (15 794 participants) observational studies at moderate to high risk of bias. Overall prevalence of diabetes and hypertension was 12% (95% confidence interval [CI], 10-15; n = 12 870; I [SUP]2[/SUP]: 89%), and 17% (95% CI, 13-22; n = 12 709; I [SUP]2[/SUP]: 95%), respectively. In severe Covid-19, the prevalence of diabetes and hypertension were 18% (95% CI, 16-20; n = 1099; I [SUP]2[/SUP]: 0%) and 32% (95% CI, 16-54; n = 1078; I [SUP]2[/SUP]: 63%), respectively. Unadjusted relative risk for intensive care unit admission and mortality were 1.96 (95% CI, 1.19-3.22; n = 8890; I [SUP]2[/SUP]: 80%; P = .008) and 2.78 (95% CI, 1.39-5.58; n = 2058; I [SUP]2[/SUP]: 75%; P = .0004) for diabetics; and 2.95 (95% CI, 2.18-3.99; n = 1737; I [SUP]2[/SUP]: 0%; P < .001) and 2.39 (95% CI, 1.54-3.73; n = 3107; I [SUP]2[/SUP]: 66%; P < .001) for hypertensives. Neither diabetes (1.50; 95% CI, 0.90-2.50; n = 1991; I [SUP]2[/SUP]: 74%; P = .119) nor hypertension (1.48; 95% CI, 0.99-2.23; n = 2023; I [SUP]2[/SUP]: 69%; P = .058) was associated with severe Covid-19. In conclusion, the risk of intensive care unit admission and mortality for patients with diabetes or hypertension who developed Covid-19 is increased compared with those without these comorbidities.
Prospero registration number: CRD42020176582.
Keywords: Covid-19; SARS-CoV-2; diabetes mellitus; endocrinology; hypertension.